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knee osteoarthritis”To the Editor: The 2014 OARSI Guidelines1 for the management
of hip and knee osteoarthritis (OA) with pharmacological therapies
are indeed improved by reference to the 2008/2010 OARSI recom-
mendations because the presence or absence of co-morbidities is
taken into account.
However, by deﬁning treatment appropriateness simply as
appropriate, uncertain and not appropriate, the 2013 recommenda-
tions do not specify how to treat the OA in a signiﬁcant number of
patients: those with moderate and high co-morbidities risks. For
these patients, the appropriateness of any oral treatment is uncer-
tain, except IACS and duloxetine. To illustrate the importance of the
population with OA and co-morbidity risks, among the US popula-
tion with OA, less than 65 years old, the prevalence of metabolic
syndrome is 59%, hypertension 75%, abdominal obesity 63%, hyper-
glycemia 30%, and renal impairment 37%; indeed, aging and obesity
should also be considered co-morbidities2. It has to be emphasized
that these patients with co-morbidities are exposed to polyphar-
macy and therefore, at risk of drugedrug interactions and of serious
adverse events.
Keeping in mind that clinical practice guidelines (CPG) are not
easily applicable to patients with co-morbidities, primarily in older
patients3, it may be important to remember before deﬁning the
treatment of patients with OA and co-morbidities the aphorism
“primum non nocere”. Accordingly, since in patients with co-
morbidities the effect of all oral drugs has been classiﬁed as uncer-
tain (except duloxetine), the appropriate oral drug to use should be
among the drugs that produce less adverse effects and those who
are less prone to produce a drugedrug interaction.
Among the drugs listed in the 2013 OARSI recommendations,
the safest drugs, almost devoid of drugedrug interactions, are the
SYSADOAs chondroitin sulfate and glucosamine chloride/sulfate.
The effect size for pain ranges from 0.18 to 0.75 for chondroitin sul-
fate and 0.17 to 0.47 for glucosamine chloride/sulfate. The symp-
tomatic response may vary from one patient to another, but
between half and two thirds of patients do respond rather satisfac-
torily to SYSADOAs.
The use of SYSADOAs does not require gastroprotection, which is
recommended for patients with moderate or high co-morbidity
risks, even when NSAIDs are considered not appropriate. This
recommendation for patients with moderate and high co-
morbidity risk should be better explained and/or revised, because
gastroprotection with proton-pump inhibitors increase cardiovas-
cular risk, in presence or not of clopidogrel [hazard ratio 1.29 (CI,
1.21e1.37)] and aspirin [hazard ratio 1.46 (CI, 1.33e1.61)]4.DOI of original article: http://dx.doi.org/10.1016/j.joca.2014.01.003.
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NSAIDs may increase signiﬁcantly the cardiovascular risks. In
contrast to NSAIDs and acetaminophen, SYSADOAs may reduce car-
diovascular mortality5.
Due to the signiﬁcant number of patients with OA and co-
morbidity risks, from a clinical point of view, the 2013 OARSI rec-
ommendations should explicitly recommend the use for 3e6
months of SYSADOAs in elderly patients and patients with co-
morbidities. Appropriateness of treatment should then be revised.
It is striking to realize that the 2013 OARSI recommendations
consider chondroitin sulfate and glucosamine chloride/sulfate as
uncertain or not appropriate for disease modiﬁcation, when RCTs
have demonstrated that glucosamine6 and chondroitin sulfate7
diminish the progression of the narrowing of the joint space width.
Several meta-analyses have conﬁrmed these reports8. Supporting a
disease modiﬁcation effect, during an 8 years follow-up, glucos-
amine reduced total knee replacement by 57%6. There is prelimi-
nary evidence that 12 months treatment with chondroitin sulfate
reduces total knee replacement by approximately 50% during 4
years follow-up. OARSI recommendations give a false impression
on the effect of SYSADOAs as structure modifying.
It is also striking that the Panel considered duloxetine as an
appropriate therapy for patients with and without co-morbidities
when this drug has a black box warning due to increased suicidal-
ity, in addition of a very long list of serious adverse effects, contra-
indications and cautions. Moreover the effect size is unknown.
In summary, since recommendations on how to treat a disease
and not a patient may have undesirable effects, the clinician has
to be aware of the potential limitations of any treatment and the al-
ternatives. In the case of knee OA, due to aging, obesity and the
presence of co-morbidities, clinicians should be advised to start
symptomatic treatment with the drugs presenting the smaller po-
tential to harm the patient.
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